{"name":"CRISPR Therapeutics AG","slug":"crispr","ticker":"CRSP","exchange":"NASDAQ","domain":"crisprtx.com","description":"CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.","hq":"Zug, Switzerland","founded":0,"employees":"","ceo":"Samarth Kulkarni","sector":"Gene Editing / Biotech","stockPrice":50.75,"stockChange":-2,"stockChangePercent":-3.79,"marketCap":"$4.9B","metrics":{"revenue":289590000,"revenueGrowth":68.6,"grossMargin":0,"rdSpend":284806000,"netIncome":-581599000,"cash":347559000,"dividendYield":0,"peRatio":-12.7,"fiscalYear":"FY2019"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2035-06-01","label":"CTX001 patent cliff ($0.0B at risk)","drug":"CTX001","type":"patent_expiry","sentiment":"negative"},{"date":"2037-06-01","label":"CTX101 patent cliff ($0.0B at risk)","drug":"CTX101","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"CTX131","genericName":"CTX131","slug":"ctx131","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"CTX131","genericName":"CTX131","slug":"ctx131","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[{"date":"2023-02-23","type":"regulatory","headline":"FDA Grants Fast Track Designation to CTX001 for Sickle Cell Disease","summary":"The FDA granted Fast Track designation to CTX001 for the treatment of sickle cell disease, a rare genetic disorder.","drugName":"CTX001","sentiment":"positive"},{"date":"2022-08-04","type":"earnings","headline":"CRISPR Therapeutics Reports Second Quarter 2022 Financial Results","summary":"CRISPR Therapeutics reported its second quarter 2022 financial results, with a net loss of $134.6 million.","drugName":"","sentiment":"neutral"},{"date":"2022-06-15","type":"deal","headline":"CRISPR Therapeutics and Bayer Enter into Global Collaboration for Gene Editing Therapies","summary":"CRISPR Therapeutics and Bayer entered into a global collaboration to develop and commercialize gene editing therapies for various diseases.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTFBCcTNHbThhaEJuTmlSaVZHQWRVYmhMUEdfWUpkRmowSkkybzhOV25HUjlfX1NtOVprODhma0NfdWgtb0tVYXRLNlFWS3plUDN4LUE?oc=5","date":"2026-04-07","type":"pipeline","source":"Yahoo Finance Singapore","summary":"CRISPR Therapeutics AG (CRSP) stock price, news, quote and history - Yahoo Finance Singapore","headline":"CRISPR Therapeutics AG (CRSP) stock price, news, quote and history","sentiment":"neutral"},{"date":"2026-03-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQNVRiQmpzbVVnM2RUR2tRZHhfLUlSaDlDbWhIRHdfWjg5YUc2dGM4Wmh2YVJoMnFBOTIyaUdVc1I3WWp0NjZ1eDlPUjBMUUNaZWVnajRqam5OekNKNl9lRFZEbFMwd05vOFFOU3A2c3cxZm14U2ZnQWRYTEY3RVU2WDZxaGhHeDM1UFdN?oc=5","date":"2026-03-10","type":"pipeline","source":"Finviz","summary":"Here is Why CRISPR Therapeutics (CRSP) Appears so Good - Finviz","headline":"Here is Why CRISPR Therapeutics (CRSP) Appears so Good","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQUWwwQkpPWXNiRUM2SjM3emo0aWZmUlBhMl9NcFd2V2pnT3VfLXhHRXd1cEJKS3h5Y3NmcFBCWE1CMS03bjA3ckZRS3NrMV9Wb1NDQ0RkRGFJYmI5V1hIMlNmb292bXI5WGwxSFUtTXNhQ2ZJQWtkVzZ2Z0hLbE1kbUJYMVVTeHk4Sk53c3V6N0RDdGFoZURNWDFZeTdGUXQzV3NlV2JzMzU5TVU?oc=5","date":"2026-03-09","type":"deal","source":"Seeking Alpha","summary":"Is A Vertex Buyout Of Crispr Therapeutics Inevitable? Here's My Take (NASDAQ:CRSP) - Seeking Alpha","headline":"Is A Vertex Buyout Of Crispr Therapeutics Inevitable? Here's My Take (NASDAQ:CRSP)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE1vN0ZSV0Y5Nnd2a1NBZVZSeFZNZU1Uakstamd3eDhnZjVkRG84cWlPRGphRm5UTnYyNWd0cDhmTVJZMHNnTDNSQVduRHFqeVF0WnBIdDNJN1JwMDVOaWRyWlBuRkpyOFd5Tl84M2VIYlNvZHlfSGFLRQ?oc=5","date":"2026-02-27","type":"deal","source":"U.S. News Money","summary":"7 Top Gene-Editing Stocks to Buy - U.S. News Money","headline":"7 Top Gene-Editing Stocks to Buy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxObmlMOXg5WlVZcW9XZVNpaUxmczgtSUpaV0hfX25NSzZzXzBuRHY5Z1Y3VHZaVFpXX2czMEllbDNBTUhOanpYc3U4SVQ4NVRGbzNmb0pPTG1yLWMtdVptX1QyZjIxZ05UbVRpOWV0Tm5RdDJ3cGFNWkpsaV9EY04wZ0cyV3hsUUhmTk5Mamp4N1l2ZzlSNURObEI4SUp0dkd4Y1ctY2Yyb2FqRTR0RVBPWjJ3?oc=5","date":"2026-02-26","type":"pipeline","source":"GuruFocus","summary":"Crispr Therapeutics (CRSP) Shares Surge on Takeover Speculation - GuruFocus","headline":"Crispr Therapeutics (CRSP) Shares Surge on Takeover Speculation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgJBVV95cUxOSmJXRm9xaDN5blJvLXZ0ZUt0RGxlVUNxUVlOOXNCS1doYmRibjRkVWlQY1FvalFoUGVEYXRyb0Z0bElOcFZOOUxaLUE0RkdpdGQ3VUo3MjZWNHpHbUI0a2hDQTk5Um03bzI0WkhXeXJXTFhTWmR5Z1hleUFjUklwVzVoT2RSWGw1VU1KNmVzWlg3bDd3VC1teFJqZWJKRnpyMnVaUE8tSjJGQ1ZSc1VqbnpKRFhjN2w4ckVNWDNNdEdtbGd1VldVUGhsX09hQnRUcHh5NHdPSzR2X3diVTUzTkpPc1MtcFA1Z3BNNWpTWWtoSnY4cjRZc0kyWmlJdzdqZlBuZGlGWVBieDQ0Nm1aT05ZNk5RY2tGSE1BQWw5WmVTNENyclgzVkZhYmRxTXl2eFBSVUxB?oc=5","date":"2026-02-18","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Galapagos (GLPG) and West Pharmaceutical Services (WST) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Galapagos (GLPG) and West Pharmaceutical","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiRkFVX3lxTE1XdnRGbFVMM3hHa2Ezc2prYmZkQWZ1elNoM0Fqc0dBNE1scDc4RmJpZThtUzkwbkFGZjhNZWs0ak44WWVoakE?oc=5","date":"2026-02-14","type":"earnings","source":"MEXC Exchange","summary":"CRISPR Therapeutics (CRSP) Stock: Why Bad Earnings Sparked a 9% Rally - MEXC Exchange","headline":"CRISPR Therapeutics (CRSP) Stock: Why Bad Earnings Sparked a 9% Rally","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOYk5HOVp0VEY4eVREUlpuZmZYREVlUHlUUXJORW1xV05EUnA0STctNl9KOXh6aXFIVXpJYk9ZZkl5aGx1b1d4b0JDQ2pjQmRtYTZGbjlmRF9jcXdjVWg2dTJwbDhrNjZ6UHF2QjRsaDZqMFpkSE9BMTllMGVCQ2lfT3FZc0V0aEFURkw5bm96RllpQUtVWkZoMA?oc=5","date":"2026-02-13","type":"earnings","source":"Finviz","summary":"CRSP Posts Wider-Than-Expected Loss in Q4, Sales Miss Estimates - Finviz","headline":"CRSP Posts Wider-Than-Expected Loss in Q4, Sales Miss Estimates","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMijAJBVV95cUxQcW1UdV8wbGtwTTlScHRfUk1EYW1GVFNiWDdjSjhXYlBsc1hlOEpZMUg2LXN0aDN5dmpjbFRyTDJVWmMzWGExdmw5WDhPVWJOQUluSlBJTkFPOUl2TEM0ak9qd3F3Znd2ZE15XzVBNWMzSkJuYjczeUJhR2NUaVd6NE9XWnFhcU1heGszaGJNT0I1MW5YcmJ6cWZCRUh0WTZneGJaUHZraTQxaTg5ODVsNDZrVWVxQlpBOURoY1ZXWmYyRVZQUFNNSGZRWFBtal9tM0FWYmlKYnVjQUViSktMaF91X0t6YzVtS3hoRERJVXl2TnNWOEFWQkZDQWcxZjg1SGlRTmQzMjNmd3VM?oc=5","date":"2026-02-12","type":"earnings","source":"GlobeNewswire","summary":"CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewswire","headline":"CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results","sentiment":"neutral"},{"date":"2026-02-12","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE1LVzQxbTd5SlM0VzVDWWU4dGxVUUk1SGFkc3RncGc4OFB5dTJfN1VQS3pzVGVWV3RtZjJ5NHBRc3FqLVBBTmMzS2pKRkxiQXhEeEhPWGs2ejVmTlRQUkZiRDhaTmg1TVNpRmc?oc=5","date":"2026-02-05","type":"deal","source":"Morningstar","summary":"The Best Biotech Stocks to Buy - Morningstar","headline":"The Best Biotech Stocks to Buy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxObzF0TTBLYk5fWHBOeDdzVkd6NW55Ujc1WEVDNHR3S2NLVVhFaGIyZndXZ2xwQ04wdGwtazZlLVhNRE1uUHg5RUNEeXhfREZydnlKZXhnZnVrck5yZ2I1V0thdVZmT0JmTVY1NEpJSU80SldMV2UzT0tBdExBOTdqUUM0OHFzcG8?oc=5","date":"2025-09-18","type":"pipeline","source":"Seeking Alpha","summary":"CRISPR stock wins new overweight at J.P. Morgan (CRSP:NASDAQ) - Seeking Alpha","headline":"CRISPR stock wins new overweight at J.P. Morgan (CRSP:NASDAQ)","sentiment":"neutral"}],"patents":[{"drugName":"CTX001","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":0},{"drugName":"CTX101","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2037-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Editas Medicine","Intellia Therapeutics","Beam Therapeutics"],"therapeuticFocus":["Sickle Cell Disease","Beta Thalassemia"],"financials":{"source":"sec_edgar+yahoo","revenue":289590000,"revenuePeriod":"2019-12-31","revenueHistory":[{"value":289590000,"period":"2019-12-31"},{"value":211928000,"period":"2019-09-30"},{"value":318000,"period":"2019-06-30"},{"value":328000,"period":"2019-03-31"},{"value":3124000,"period":"2018-12-31"},{"value":563000,"period":"2018-09-30"}],"grossProfit":-213480000,"grossProfitHistory":[{"period":"2025-12-31","value":-213480000},{"period":"2024-12-31","value":-85667000},{"period":"2023-12-31","value":239750000},{"period":"2022-12-31","value":-109814000}],"rdSpend":284806000,"rdSpendHistory":[{"period":"2025-12-31","value":381059000},{"period":"2024-12-31","value":310236000},{"period":"2023-12-31","value":387332000},{"period":"2022-12-31","value":461645000}],"sgaSpend":73542000,"operatingIncome":-664571000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-664571000},{"period":"2024-12-31","value":-466566000},{"period":"2023-12-31","value":-222538000},{"period":"2022-12-31","value":-673161000}],"netIncome":-581599000,"netIncomeHistory":[{"period":"2025-12-31","value":-581599000},{"period":"2024-12-31","value":-366252000},{"period":"2023-12-31","value":-153610000},{"period":"2022-12-31","value":-650175000}],"eps":-6.47,"epsHistory":[{"period":"2025-12-31","value":-6.47},{"period":"2024-12-31","value":-4.34},{"period":"2023-12-31","value":-1.94},{"period":"2022-12-31","value":-8.36}],"cash":347559000,"cashHistory":[{"period":"2025-12-31","value":347559000},{"period":"2024-12-31","value":298257000},{"period":"2023-12-31","value":389477000},{"period":"2022-12-31","value":211885000}],"totalAssets":2265243000,"totalLiabilities":343430000,"totalDebt":206746000,"equity":1921813000,"operatingCashflow":-345014000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-345014000},{"period":"2024-12-31","value":-142774000},{"period":"2023-12-31","value":-260375000},{"period":"2022-12-31","value":-495741000}],"capex":-25914000,"capexHistory":[{"period":"2025-12-31","value":-25914000},{"period":"2024-12-31","value":-1901000},{"period":"2023-12-31","value":-11970000},{"period":"2022-12-31","value":-37188000}],"freeCashflow":-370928000,"dividendsPaid":null,"buybacks":null,"employees":0,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":17183000,"ebit":-130248000,"ebitda":-125929000,"period":"2026-03-31","revenue":1000000,"epsBasic":-1.28,"netIncome":-122931000,"rdExpense":68574000,"epsDiluted":-1.28,"grossProfit":-44949000,"operatingIncome":-130248000},{"sga":18399000,"ebit":-154764000,"ebitda":-149103000,"period":"2025-12-31","revenue":0,"epsBasic":-1.37,"netIncome":-130613000,"rdExpense":83526000,"epsDiluted":-1.37,"grossProfit":-53703000,"operatingIncome":-154764000},{"sga":16931000,"ebit":-132059000,"ebitda":-127626000,"period":"2025-09-30","revenue":0,"epsBasic":-1.17,"netIncome":-106441000,"rdExpense":58902000,"epsDiluted":-1.17,"grossProfit":-57115000,"operatingIncome":-132059000},{"sga":18916000,"ebit":-229324000,"ebitda":-224675000,"period":"2025-06-30","revenue":0,"epsBasic":-2.4,"netIncome":-208549000,"rdExpense":166147000,"epsDiluted":-2.4,"grossProfit":-45153000,"operatingIncome":-229324000},{"sga":19296000,"ebit":-148424000,"ebitda":-143688000,"period":"2025-03-31","revenue":0,"epsBasic":-1.58,"netIncome":-135996000,"rdExpense":72484000,"epsDiluted":-1.58,"grossProfit":-57509000,"operatingIncome":-148424000}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":50.75,"previousClose":52.75,"fiftyTwoWeekHigh":78.48,"fiftyTwoWeekLow":34.87,"fiftyTwoWeekRange":"34.87 - 78.48","fiftyDayAverage":51.82,"twoHundredDayAverage":56.03,"beta":1.74,"enterpriseValue":3433530880,"forwardPE":-12.7,"priceToBook":2.7,"priceToSales":1192.97,"enterpriseToRevenue":836.83,"enterpriseToEbitda":-6.46,"pegRatio":0,"ebitda":-531080000,"ebitdaMargin":0,"freeCashflow":-260895744,"operatingCashflow":-399964000,"totalDebt":787641984,"debtToEquity":43.4,"currentRatio":17.96,"returnOnAssets":-14.1,"returnOnEquity":-31.2,"analystRating":"2.0 - Buy","recommendationKey":"buy","numberOfAnalysts":22,"targetMeanPrice":82.55,"targetHighPrice":291,"targetLowPrice":33,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":5.9,"institutionHeldPercent":77.2,"sharesOutstanding":96448792,"floatShares":96018630,"sharesShort":22484150,"shortRatio":12.9,"shortPercentOfFloat":23.3,"epsTrailing":-6.17,"epsForward":-4,"revenuePerShare":0.04,"bookValue":18.83,"officers":[{"age":47,"name":"Dr. Samarth  Kulkarni Ph.D.","title":"CEO & Chairman"},{"age":41,"name":"Dr. Raju Yashaswi Prasad Ph.D.","title":"Chief Financial Officer"},{"age":53,"name":"Mr. James R. Kasinger J.D.","title":"General Counsel & Secretary"},{"age":53,"name":"Dr. Naimish  Patel C.M., M.D.","title":"Chief Medical Officer"},{"age":null,"name":"Mr. Shaun  Foy CFA","title":"Co-Founder"},{"age":null,"name":"Dr. Emmanuelle Marie Charpentier Ph.D.","title":"Co-Founder & Scientific Advisory Board Member"},{"age":null,"name":"Dr. Craig C. Mello Ph.D.","title":"Scientific Founder & Advisory Board Member"},{"age":53,"name":"Dr. Chad A. Cowan Ph.D.","title":"Scientific Founder"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.crisprtx.com","phone":"41 41 561 32 77"}}